Obesity 肥胖

COND-obesity

4

interventions reviewed

A

top legacy tier

1

counter-evidence

A Moderate evidence 1

Tirzepatide (Mounjaro / Zepbound / 穆桂諾)

Published with Warning 🚨 High market risk

B Preliminary 1

Semaglutide (Ozempic / Wegovy / Rybelsus / 胰妥讚)

AI preliminary rating · view reasons and limits

C Weak 1

三重激動劑 Retatrutide

Published with Warning

D Counter-evidence 1

Bitter Melon Peptide (mcIRBP-19 / MAP30)

苦瓜胜肽（山苦瓜胜肽 / mcIRBP-19）

Insufficient Evidence ⚠️ Moderate market risk